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Abstract
Background: Prospective efficacy monitoring of anti-malarial treatments is imperative for timely detection of
resistance development. The in vivo efficacy of artesunate-amodiaquine (ASAQ) fixed-dose combination (FDC) was
compared to that of artemether-lumefantrine (AL) among children aged six to 59 months in Nimba County, Liberia,
where Plasmodium falciparum malaria is endemic and efficacy data are scarce.
Methods: An open-label, randomized controlled non-inferiority trial compared the genotyping adjusted day 42
cure rates of ASAQ FDC (ASAQ Winthrop®) to AL (Coartem®) in 300 children aged six to 59 months with
uncomplicated falciparum malaria. Inclusion was between December 2008 and May 2009. Randomization (1:1) was
to a three-day observed oral regimen (ASAQ: once a day; AL: twice a day, given with fatty food). Day 7
desethylamodiaquine and lumefantrine blood-concentrations were also measured.
Results: The day 42 genotyping-adjusted cure rate estimates were 97.3% [95% CI: 91.6-99.1] for ASAQ and 94.2%
[88.1-97.2] for AL (Kaplan-Meier survival estimates). The difference in day 42 cure rates was −3.1% [upper limit
95% CI: 1.2%]. These results were confirmed by observed proportion of patients cured at day 42 on the per-
protocol population. Parasite clearance was 100% (ASAQ) and 99.3% (AL) on day 3. The probability to remain free of
re-infection was 0.55 [95% CI: 0.46-0.63] (ASAQ) and 0.66 [0.57-0.73] (AL) (p = 0.017).
Conclusions: Both ASAQ and AL were highly efficacious and ASAQ was non-inferior to AL. The proportion of
patients with re-infection was high in both arms in this highly endemic setting. In 2010, ASAQ FDC was adopted as
the first-line national treatment in Liberia. Continuous efficacy monitoring is recommended.
Trial registration: The protocols were registered with Current Controlled Trials, under the identifier numbers
ISRCTN51688713, ISRCTN40020296.
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Background
Despite notable decreases in malaria incidence rates in
various endemic settings, Plasmodium falciparum malaria
remains a serious public health problem especially for
the African continent [1]. Potent artemisinin-containing
combination therapy (ACT) is the recommended first-
line treatment for uncomplicated falciparum malaria in
most endemic countries [2]. This includes artesunate-
amodiaquine (AS + AQ), artemether-lumefantrine (AL),
artesunate-mefloquine (AS-MQ), artesunate-sulfadoxine-
pyrimethamine (AS-SP) and dihydroartemisinin-
piperaquine (DHAPQ), which are considered efficacious
and safe [2-5]. Fixed-dose combinations (FDC) should be
used whenever possible to support adherence. The first
FDC of AS + AQ (ASAQ Winthrop®) was developed by
the Drugs for Neglected Diseases initiative (DNDi), and is
currently registered in 32 African countries. ASAQ FDC
was shown to be efficacious, safe and well tolerated in pre-
vious studies [6-9].
Prospective periodic monitoring of the efficacy of anti-
malarial treatments by in vivo studies is part of post-
marketing surveillance [10]. Monitoring of ACT becomes
particular important in the light of recent emergence of
artemisinin resistance in South-East Asia [11-13]. In
Liberia, the national treatment protocol for uncomplicated
falciparum malaria was AS + AQ (separate tablets) since
2003, though only limited information was available on
the efficacy of ACT in this highly malaria endemic country
[14]. The present study assessed the in vivo efficacy of
ASAQ FDC compared to that of artemether-lumefantrine
in a non-inferiority trial among 300 children aged six to
59 months in Nimba County, a falciparum malaria en-
demic region in Northern Liberia. At the same site, both
treatments were also studied in children over five years of
age and adults in a parallel randomized trial with 28 days
follow-up and the primary objective to obtain data on the
safety and tolerability in this under-studied age group.
The methods and findings of this second trial are reported
in detail elsewhere [15] but a summary of efficacy results
in the older age group are included here.
Methods
Study site, objectives and design
An open-label, randomized non-inferiority trial was
carried out between December 2008 (first inclusion) and
July 2009 (last scheduled follow up visit) in the Compre-
hensive Healthcare Center (CHC) of Saclepea, Nimba
County. The facility was supported by Médecins Sans
Frontières and the Ministry of Health and served the
local population and displaced persons from Ivory Coast
in a nearby refugee camp. The primary objective was to
evaluate the efficacy of amodiaquine-artesunate versus
artemether-lumefantrine among children between six and
59 months old suffering from uncomplicated malaria
defined as the genotype adjusted cure rates at day 42 [10].
Secondary objectives were: (a) to evaluate the genotype-
unadjusted cure rates at day 42, genotype adjusted/
unadjusted cure rates at day 28, and re-infection rates at
day 42; (b) to assess blood drug concentration differences
possibly influencing efficacy by measuring drug concen-
trations of amodiaquine and lumefantrine at day 0 and
day 7; (c) to assess the safety of amodiaquine-artesunate
and artemether-lumefantrine treatment among children
between 6 and 59 months by documenting adverse events
that occurred during the study before day 28 and by
documenting serious adverse events; (d) to formulate rec-
ommendations for adapted case management of malaria in
Nimba County. The findings on tolerability and safety (sec-
ondary objective (c)), are described in detail elsewhere [15].
Inclusion criteria were: age six to 59 months; fever
(axillary temperature ≥ 37.5°C) or fever in previous 48
hours; blood smear-confirmed asexual stages of falcip-
arum malaria (P. falciparum mono-infection) and parasite
density between 2,000–200,000/μl blood; high probability
of attending follow-up; signed informed consent (patient
or responsible caregiver). Exclusion criteria were: severe/
complicated malaria [16]; severe anaemia (<5 g/dl haemo-
globin (Hb)); full course of AS + AQ or AL in the past 10
days; known hypersensitivity to the study drugs; concomi-
tant febrile illness other than malaria that may confound
outcome; severe malnutrition (weight-for-height < 70% of
median and/or symmetrical edema involving at least the
feet). Previous intake of anti-malarials other than AS +
AQ or AL did not lead to exclusion from study participa-
tion, Study visits were on Days 0, 1, 2, 3, 7, 14, 21, 28, 35
and 42. Patients were not routinely hospitalized for study
participation unless required for treatment of any clinical
presentations during study follow up. All routine mea-
sures that were performed during study visits are de-
scribed below.
Randomization, drug allocation and blinding
Inclusion was between December 2008 and May 2009. Pa-
tients HRP-2 rapid diagnostic test-positive (Paracheck®)
were screened for inclusion by clinical examination, malaria
blood smear, Hb measure (capillary blood, HemoCue®). Eli-
gible patients were randomized at 1:1 ratio to ASAQ or AL.
Random allocation (computer-generated, block size of 6,
study site unaware of block size) was provided in sealed,
opaque individual envelopes which were opened in con-
secutive order by study nurses at drug allocation. Allocation
was not disclosed to the medical staff performing the clin-
ical exams, but different intake schedules of ASAQ and AL
may have compromised full masking. The laboratory team
was un-blinded to treatment allocation since blood spots
for lumefantrine concentration assessment (AL arm) were
collected on filter-paper pre-treated with tartaric acid.
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Treatment
Treatment by study arm was on days 0, 1 and 2. ASAQ
(ASAQ Winthrop®, Sanofi-Aventis) was given once a day
without co-administration of food, though breast feeding
for infants in the ASAQ arm around the time of drug
intake was not discouraged. AL (Coartem®, Novartis)
was given as two doses per day, 6–12 hours between
doses, and administered with a high-fat cookie. For small
children the cookie was given as a paste mixed with
water or breast-feeding was encouraged. Both treatments
were administered with a glass of water. For infants who
could not swallow tablets, tablets were dissolved (ASAQ)
or crushed and mixed (AL) with a small volume of water.
Both treatments were three-day oral regimens dosed by
weight according to the manufacturer’s instructions:
ASAQ Winthrop® 5 to <9 kg: one tablet/day of artesunate
(AS) 25 mg/amodiaquine (AQ) 67.5 mg; 9 to <18 kg: one
tablet/day of AS 50 mg/AQ 135 mg; 18 to <36 kg: 1 tab-
let/day of AS 100 mg/AQ 270 mg; ≥36 kg: 2 tablets/day of
AS 100 mg/AQ 270 mg. Coartem® tablet strength was
20 mg artemether/120 mg lumefantrine: 5 to <15 kg: 1
tablet/dose; 15 to <25 kg: 2 tablets/dose; 25 to <35 kg: 3
tablets/dose; ≥ 35 kg 4 tablets/dose. The children’s weight
was rounded to the nearest kg for dosing of the study
drug. All doses were administered in the study site and ob-
served for 30 minutes. If vomited/spat-out within 30 mi-
nutes, a full-dose was re-administered. If again vomited/
spat-out within 30 minutes, the patient was withdrawn and
rescue treatment given (parenteral quinine or intramuscu-
lar artemether). In the event of treatment failure and in the
absence of signs of severe malaria, patients in the AL arm
were treated with ASAQ Winthrop, and patients in the
ASAQ arm were treated with AL (administered with a fatty
cookie) and terminated from further study follow-up. The
first dose of rescue treatment was given in the study site,
observed for 30 minutes and re-administered in case of
vomiting.
Blood smear follow up and parasite genotyping
Giemsa-stained malaria thin and thick blood smears
were prepared from capillary blood on days 0, 2, 3, 7, 14,
21, 28, 35 and 42. Trophozoites were counted against
500 white blood cells (WBCs) in the thick smear, assum-
ing an average of 8000 WBCs / μl blood. For high para-
sitaemia, parasites were counted against 1000 red blood
cells in the thin smear. Plasmodium species and parasite
blood stages were differentiated on the thick smear in at
least 30 high power fields, and confirmed on the thin
smear. All blood smears were read by a second reader
blinded to the first reader’s result. Readings of two
readers in agreement were reported as final result. For
discrepant slides the final reading was by the lab super-
visor or a designated senior reader. External quality
control (EQC) was performed by the Shoklo Malaria
Research Unit (SMRU) in Mae Sot, Thailand, on 10% of
all day 0 enrolment slides, 10% of all day 2 slides, 10% of
all negative follow-up slides and all failure slides.
For each patient at enrolment, and on any follow up
day with blood-smear-confirmed recurrent parasitaemia,
two blood spots were prepared from capillary or venous
blood (in EDTA) onto filter paper (Whatman FTA®cards)
for parasite genotyping to distinguish between falcip-
arum malaria recrudescence and re-infection, using
three genetic markers (glurp, msp1, msp2) as described
elsewhere [17]. In the second trial on the tolerability of
ASAQ and AL among 1000 patients aged >5 years with
uncomplicated falciparum malaria (1:1 randomized to
ASAQ or AL, details reported elsewhere) the malaria
blood smear follow up was limited to days 0, 2 and 28,
day 3 if positive on day 2 [15], and any visit if fever.
Clinical monitoring and laboratory follow up
At each visit a standardized symptoms questionnaire
and physical examination were conducted by trained
study physician assistants. Vital signs (pulse rate, respira-
tory rate, and blood pressure) were recorded on day 0
and 28 for all patients. Fever was assessed at every visit
by measuring the axillary temperature with a digital
thermometer. Temperatures > 37.5°C were recorded as
fever. Haemoglobin (Hb) was measured on each visit
(finger-prick capillary blood, HemoCue®), and liver func-
tion tests were conducted by assessment of blood levels
of aspartate aminotransferase (AST) and alanine amino-
transferase (ALT) (Reflotron plus®, Roche Diagnostics)
on days 0 and 28. A full blood count (FBC) was done on
days 0, 7 and 28 (Act5diff, Beckman Coulter®), or if the
HemoCue® result indicated anaemia (defined as <10 g/dl
Hb for children < 2 years, <11 g/dl Hb for children > 2
years) [18]. Clinical- or laboratory signs and symptoms
which occurred or worsened at any time after the first
drug intake up to day 28 were recorded as adverse
events (AEs) to document tolerability and safety (for de-
tails on adverse event recording and results [15].
Sample size
The sample size calculation was based on an assumed
efficacy of 96% for both ACTs, a non-inferiority margin
of 6%, a power of 80%, and a one-sided 5% significance
level. To this end 132 children per study arm were re-
quired (nQuery Advisor). With a 10% lost to follow up
rate, the total number of children was rounded to 300
(150 per study arm).
Efficacy outcome analysis
Efficacy analyses were conducted on both mITT (modi-
fied-intention-to-treat) and PP (per protocol) popu-
lations. The mITT population was defined as all
randomized patients with parasitological confirmation of
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falciparum malaria at day 0 who took at least one dose
of study drug. The PP population was defined as all pa-
tients who were included into the mITT population and
who did not have a major protocol deviation and who
were not pre-maturely discontinued from the study for
reasons other than an adverse event (AE) or recurrence
of parasitaemia. Major deviations were defined as: i) at
inclusion: weight < 5kg, no microscopic confirmation of
asexual stages of Pf malaria or mixed infection, asexual
parasites density < 2,000 or > 200,000 /μl of blood, no
fever (axillary temp > 37.5°C) or no history of fever in
the last 48 hours, no informed consent, presence of gen-
eral danger signs, signs of severe/complicated malaria,
severe anaemia (Hb < 5g/dL), severe malnutrition (WH
< 70%), having received a full course of the treatment
under study in the previous 10 days; ii) during study
conduct: any dose of study drug not taken or vomited
and not replaced / or delayed by ≥ 1 calendar date, two
consecutive study visits not performed in the allowed
time window [−1; +3 days], or intake of concomitant
medication (except for anti-pyretics) during follow-up if
medication is of known anti-malarial activity. Results
were reported by treatment group as allocated. Treatment
outcomes were classified using standard definitions: ad-
equate clinical and parasitological response (ACPR), early
treatment failure (ETF), late parasitological failure (LPF),
and late clinical failure (LCF) [10]. The main efficacy
endpoints were day 42-genotyping-adjusted cure rates.
Secondary efficacy endpoints were genotyping-adjusted
day 28, and genotyping-unadjusted day 28 and day 42 effi-
cacy outcome. Day 42 and day 28 cure rates were provided
through estimates of survival by Kaplan-Meier (KM)
analysis on the mITT population (mITT/KM), and by
calculation of the proportion of patients cured by day 28
or day 42, respectively, with the PP population (PP/%).
Patients with recurrent parasitaemia and missing or
inconclusive genotyping results were excluded from
genotyping-adjusted efficacy analyses and coded as failure
for genotyping-unadjusted analyses (mITT/KM and PP/%)
[10]. P. falciparum re-infections were censored at visit of
recurrence for genotyping-adjusted mITT/ KM analysis,
excluded from genotyping-adjusted PP/% analysis and
coded as failure for all genotyping-un-adjusted analyses.
Non-Pf malaria species infections were censored at visit of
recurrence for mITT/KM analyses, and excluded from
PP/% analyses. Pre-mature study discontinuations or pa-
tients with two consecutive scheduled visits not performed
in the allowed time window [−1; +3 days] were censored at
the last visit performed according to schedule for mITT/
KM analysis. Pre-mature study discontinuation due AE
were excluded from the PP/% analysis [10] (other prema-
ture discontinuations or patients with visits not performed
in the allowed time windowwere already excluded from the
PP population).
All proportions/rates were presented with a 95% confi-
dence interval (CI) by treatment group. For assessment
of non-inferiority of ASAQ versus AL, a 90% CI was
constructed around the day 42 genotyping-adjusted cure
rate difference (AL- ASAQ), and the upper limit of the CI
(= a one-sided 95% CI) was compared to the pre-set
non-inferiority margin. In addition, the Kaplan-Meier
estimated probability of remaining free of P. falciparum
re-infection (re-infection coded as failure, treatment fail-
ures or events without treatment outcome censored, pa-
tients with missing or undetermined genotyping excluded)
was assessed per treatment arm and survival curves com-
pared by log rank test. The median time to re-infection
and interquartile range (IQR) per arm were assessed and
the median compared using the Wilcoxon rank-sum test.
The proportion of patients who achieved parasite clear-
ance (asexual P. falciparum) on days 0, 2 and 3, and the
proportion of patients with gametocytes on days 0, 2, 7,
14 and 28 were assessed. Analyses were performed with
STATA 10.1. (Stata Corp, Texas), following a pre-set stat-
istical analysis plan.
Anti-malarial blood concentrations
Day 0 and day 7 blood concentrations of amodiaquine
(AQ) and desethylamodiaquine (DEAQ) (ASAQ arm), or
lumefantrine (LF) (AL arm), were assessed from venous
blood (EDTA) preserved as dried spots on filter paper
(Whatman® 31 ET). For LF samples the filter paper was
pre-treated with tartaric acid (0.75 μM) and stored refrig-
erated [19]. Blood spots were sent once per month to the
pharmacology laboratory in Paris and stored at −80°C
until analysis. AQ, DEAQ and LF blood concentrations
were measured by high performance liquid chromatog-
raphy with ultraviolet detection (LF) or by tandem-mass
spectrometry (AQ/DEAQ) with limits of quantification
(LOQ) of <2.5 ng/ml (AQ), <5.0 ng/ml (DEAQ), and <200
ng/ml (LF), respectively. Day 7 samples collected before
day 6 or after day 8 were excluded from statistical analysis
on blood concentrations. Summary statistics were pro-
vided (mITT population), and comparison of day 7 blood
concentrations between patients with day 42 efficacy
outcome ACPR versus recrudescence, or ACPR versus re-
infections, or ACPR versus combined P. falciparum recur-
rences (re-infection, recrudescence and recurrences with
missing or undetermined genotyping results) respectively,
performed (mITT, comparison by Wilcoxon rank-sum
test). Furthermore, day 0 blood concentrations of other
anti-malarials: pyrimethamine, sulfadoxine, chloroquine,
quinine were retrospectively assessed from stored serum
samples collected at baseline from each patient. Concen-
trations measures were by liquid chromatography coupled
with tandem mass spectrometry, after protein precipita-
tion by acetonitrile containing hydroxychloroquine as in-
ternal standard [20].
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Ethics
The procedures followed were in accordance with the eth-
ical standards of the Helsinki Declaration. All participants
or responsible caretakers signed informed consent. The
studies were approved by the Liberian Institute for Bio-
medical Research (LIBR) Ethics committee, the Ministry
of Health and Social Welfare, Monrovia, Liberia, and
the Comité de Protection des Personnes (CPP) Ile de
France XI (Saint Germain en Laye), France. The studies
were registered at Controlled Trials (ISRCTN51688713,
ISRCTN40020296).
Results
Inclusion, baseline characteristics and follow-up
A total of 701 pre-screened patients were checked for eli-
gibility, and 300 children were included and randomized
to the two arms (Figure 1). Demographics and baseline
parasitological- and clinical parameters were similar
between the treatment arms (Table 1). The distribution of
patients’ weight and age by weight-based drug dosage
group and study arm are provided in Additional file 1. All
randomized patients had been exposed to at least one
dose of the study drug. All but one patient who partici-
pated twice (ASAQ arm, second participation excluded
from all analyses) were included to the mITT population
(n = 149 ASAQ, n = 150 AL) (Figure 1). Ninety-six-point-
six percent (144/149) of patients (ASAQ, mITT) and
86.7% (130/150) of patients (AL, mITT), completed the
study treatment according to schedule (no delay ≥ 1 calen-
dar day, no dose missed). Delayed dose intake was
recorded in the AL arm for 8.7% of patients (13/150, one
or two doses delayed by one calendar day). The treatment
of these patients was completed on day 3. Few patients
had incomplete treatment: 3.4% (5/149, ASAQ) and 4.7%
n=150   
exposed to treatment 
n=150   
exposed to treatment 
ASAQ  
n=150 allocated  
Premature study discontinuation    n= 57 (38.3%)   
  Lost to follow-up   0 
  Withdrawal of consent   0 
  Unable to attend follow up visit              0 
  Serious adverse event (SAE)  2  
  Recurrence of Parasitaemia <Day42 54 * 
  Incorrect enrolment   1 ** 
n=1 excluded  
(participated twice) a
 Excluded                                                  n=401 
   < 2000 or  > 200 000 Pf parasites /µl       356 
   No asexual  Pf malaria (microscopy)       117 
   No informed consent                                  8   
   Signs of severe/complicated malaria         3
   Presence of general danger signs             3  
   Severe malnutrition (WH<70%)                 2 
   Concomitant febrile illness                         2 
Pre-mature discontinuations##          n=3 (2.0%)          
- Unable to complete follow up visits                     1                      
- Withdrawal of consent                                         2
Major protocol deviations                                   n=21 (14.0%) 
- Any treatment dose missed, vomited not  
replaced, or delayed  ≥ 1 calendar day                19 ###
- ≥ 2 consecutive visits missed              2
Major protocol deviations                         n=7 (4.7%) 
- Day0 Pf parasites < 2000 or > 200 000/µl       2 *** 
- Any treatment dose missed, vomited not  
replaced, or delayed  ≥ 1 calendar day           4 
- ≥ 2 consecutive visits missed                          1 
Premature study discontinuation:    n= 46 (30.7%)  
  Lost to follow-up    0 
  Withdrawal of consent                2 #
  Unable to attend follow up visit               1 
  Serious adverse event (SAE)   1  
  Recurrence of Parasitaemia <Day42    42  
  Incorrect enrolment    0  
Completed 42 days follow- up    n= 92 (61.3%)  
n=701 screened 
n=300 randomized 
AL 
n=150 allocated  
Completed 42 days follow- up    n= 104 (69.3%)  
n=149 
mITT 
population 
n=150 
mITT 
population 
n=142 
PP 
population 
n=126 
PP 
population 
Figure 1 Trial profile with mITT and PP populations. RDT = rapid diagnostic test for malaria (Paracheck® ); Pf = Plasmodium falciparum; WH =
Weight for Height; mITT = modified Intention to Treat; KM = Kaplan Meier; SAE = Serious Adverse Event; PP = Per Protocol. a Second participation
excluded from analyses.* Note: one patient was discontinued with recurrent malaria (Pf re-infection, day 30). This patient is listed here among the
n = 2 patients pre-maturely discontinued due to SAE (severe malaria). ** Patient was discontinued from participation on day 0 shortly upon
enrolment because eligibility criteria were not met: i.e. asexual parasites density was outside the eligibility range (< 2000 or > 200 000 / μl blood).
*** Two patients were enrolled with day 0 asexual parasites density outside the eligibility range (< 2000 or > 200 000 / μl blood): n = 1 patient
was discontinued on day 0, once the eligibility error was discovered (discontinuation due to incorrect enrolment); n = 1 patient continued the
follow-up to day 42. Both patients were excluded from the per-protocol population (protocol deviation). # Pre-mature discontinuations other than
discontinuations due to adverse event or recurrence of parasitaemia which lead to exclusion from the PP population. ## For n = 1 patient the
care-taker withdrew consent on day 3; for n = 1 patient the care-taker withdrew consent on day 21. ### n = 1 patient who also missed 2 evening
doses is not listed among these n = 19, since the primary reason for exclusion of this patients from PP population was withdrawal of consent by
care-taker (day 3) (patient listed among n = 2 consent withdrawn).
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(7/150 AL) respectively. This was either due to premature
study-discontinuation (1/149 ASAQ incorrect enrolment;
1/150 AL repeated vomiting of dose, SAE), missed visits
for dose-intake (2/150 AL, n = 1 one evening dose missed,
n = 2 two evening doses missed), or spitting-out/wasting
(part) of a dose (4/149 ASAQ arm; 4/150 AL arm).
Ninety-two patients (61.7%, ASAQ) and 104 patients
(69.3%, AL) completed 42 days of follow-up. Premature
study discontinuations were mainly due to recurrent para-
sitaemia before day 42 (Figure 1). No patient was lost to
follow-up, two caregivers had withdrawn consent for two
participating children (day 3 and day 21, respectively, AL).
Three patients were prematurely discontinued due to a
serious adverse event (SAE): one severe pneumonia (day
3, ASAQ), one severe malaria (P. falciparum re-infection,
day 30, ASAQ), and one severe vomiting (onset severe
vomiting on day 1, withdrawn and hospitalized after
repeated vomiting of day 1 evening study dose, AL). All
SAEs had outcome fully recovered. Major protocol devia-
tions and pre-mature study discontinuations other than
AE or recurrence of parasitaemia lead to exclusion from
the per-protocol population for seven (4.7%, ASAQ) and
24 (16%, AL) patients, respectively (Figure 1).
Primary efficacy outcomes
Treatment outcomes and endpoint classifications for ef-
ficacy analyses are displayed in Table 2 (mITT/KM ana-
lysis) and Table 3 (PP/% cured analysis). One patient in
the ASAQ arm and three in the AL arm experienced
treatment failure up to day 28, amounting to a total of
three (ASAQ) and six (AL) failures by day 42 (Table 2)
(mITT). All treatment failures were LPFs (days 21–42)
with exception of one ETF (day 2, AL). All failures had
completed the study treatment according to schedule,
except one LPF (skipped both day 1 doses, completed
regimen on day 3, AL arm). Among patients with recur-
rent parasitaemia, seven had missing or inconclusive
genotyping results (n = 2 ASAQ; n = 5 AL) (excluded from
genotyping-adjusted analyses). The day 42 genotyping-
adjusted cumulative cure rate estimate (mITT/ KM) was
97.3% [CI 95%: 91.6-99.1] (ASAQ) and 94.2% [88.1-97.2]
(AL), respectively (Figure 2A, Table 4). The cure rate dif-
ference (AL-ASAQ) was −3.1% with an upper limit 95% CI
of 1.2%, demonstrating non-inferiority of ASAQ to AL. Re-
sults were similar for percentage cured on the PP popula-
tion (PP/%) (Table 4).
Secondary efficacy outcomes
Day 28 genotyping-adjusted cure rate estimates were
99.3% [95.1-99.9] (ASAQ) and 97.9% [93.6-99.3] (AL)
(mITT/KM) (Table 4). Genotyping-unadjusted cure rates
were 71.2% [63.2-77.9] (ASAQ) and 87.5% [80.9-91.9]
(AL) at day 28, and 52.7% [44.3-60.5] (ASAQ) and 59.5%
[50.9-67.1] (AL) at day 42 (mITT/ KM), respectively.
Comparable results were obtained in PP/% analysis
(Table 4). The Kaplan Meier estimated probability to re-
main free of re-infection was 0.55 [95% CI 0.46-0.63] in
the ASAQ arm and 0.66 [0.57-0.73] in the AL arm (log-
rank test, p = 0.017) (Figure 2B). The median time to re-
infection was 29 days (mITT, ASAQ arm, IQR: 24–36)
and 36 days (mITT, AL arm, IQR: 29–43) (p < 0.001).
Results on PP population were similar. Day 2 parasite
clearance was 98% in both treatment arms (145/148
ASAQ; 146/149, AL), and reached 100% (147/147,
ASAQ) and 99.3% (148/149, AL) by day 3 (mITT popu-
lation). One patient remained parasitaemic on day 3 (ETF,
AL). Gametocyte carriage peaked on day 2 with 22.3% (33/
148, ASAQ) and 18.12% (27/149) and decreased to 2.4%
(3/127, ASAQ) and 0.7% (1/139, AL) by day 28 (mITT)
(Figure 3). Among patients who had no gametocytes at
baseline, gametocyte carriage also peaked on day 2 and
declined to 0.9% (1/108, ASAQ) and 0% (0/117, AL) by day
28 (Figure 3). The day 28 genotyping-adjusted cure rates
among patients >5 years (parallel tolerability trial [15]) were
98.4% [96.7-99.2] (ASAQ) and 100% (AL) (mITT/KM), and
98.3% [97.0 – 99.5] (ASAQ) and 100% (AL) (PP/% cured), re-
spectively. Few patients had presented with fever (> 37.5°C)
at enrolment (n = 49 ASAQ arm, n = 29 AL arm, mITT
population). For the majority of children history of fever in
the last 48 hours before enrolment was reported. Among
patients with fever on day 0 in the ASAQ arm, 98% were
fever-free on day 1 and 2, and 100% fever-free on day 3. Fever
clearance in the AL armwas 100% by day 1.
Table 1 Demographic and parasitological baseline
characteristics by treatment arm, mITT population
ASAQ AL
N = 149 N = 150
Sex (male), N (%) 86 (57.7) 89 (59.3)
Age (months), mean (sd) 37.2 (13.7) 37 (13.6)
Weight (kg), mean (sd) 12.8 (2.5) 12.9 (2.6)
Axillary temperature (°C), mean (sd) 37.1 (1.1) 36.9 (0.8)
Haemoglobin (g/dl) *, mean(sd) 9.2 (1.6) 9.3 (1.5)
P. falciparum trophozoites/μl,
geometric mean, (95% CI)
20020 19152
(15878–25244) (15386–23839)
P. falciparum trophozoite
density/μl, N (%)
< 2,000 0 0
2,000 - < 50,000 105 (70.5) 113 (75.3)
50,000 - < 100,000 21 (14.1) 22 (14.7)
100,000 - < 150,000 15 (10.1) 8 (5.3)
150,000 - < 200,000 6 (4.0) 7 (4.7)
> 200,000 2 (1.3) 0
P. falciparum gametocytes
carriage, N (%)
22 (14.8) 22 (14.7)
Sd standard deviation, CI confidence interval. * Hb measures by Act5diff,
Beckman Coulter®.
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Day 7 blood concentrations of AQ, DEAQ, LF
Blood concentrations of amodiaquine (AQ), desethyla-
modiaquine (DEAQ) (ASAQ arm) and lumefantrine (LF)
(AL arm) were assessed from day 0 (baseline) and day 7
blood samples. Amodiaquine-intake shortly before study
inclusion (protocol violation) was evident for six patients
(ASAQ arm) who had quantifiable day 0 AQ levels (range:
3.6 – 34 ng/ml). Three of these had also high DEAQ levels
(>200 ng/ml). Seventy-eight patients had low DEAQ
blood concentrations on day 0 (range: 5.0 -142 ng/ml),
Table 2 Efficacy endpoint classification at day 28 and day 42, - mITT/KM analysis
Treatment outcome Day 28 Day 42
mITT population, N (%) ASAQ AL ASAQ AL KM analysis
N = 149 N = 150 N = 149 N = 150
ACPR 104 (69.8) 123 (82.0) 77 (51.7) 82 (54.7) Success
ETF 0 1 (0.7) 0 1 (0.7) Failure
LCF or LPF
- P. falciparum recrudescence 1 (0.7) 2 (1.3) 3 (2.0) 6 (4.0) Failure
- P. falciparum re-infection 39 (26.2) 13 (8.7) 64 (43.0) 45 (30.0) Censored*
- undetermined or missing PCR 2 (1.3) 2 (1.3) 2 (1.3) 5 (3.3) Excluded*
Non-P. falciparum malaria infection ** 0 3 (2.0) 0 5 (3.3) Censored
No treatment outcome
- discontinued for SAE # 1 (0.7) 1 (0.7) 1 (0.7) 1 (0.7) Censored
- withdrawal after incorrect enrolment ## 1 (0.7) 1 (0.7) Censored
- unable to complete follow-up visits 1 (0.7) 1 (0.7) Censored
- withdrawal of consent 2 (1.3) 2 (1.3) Censored
- ≥ 2 consecutive visits not performed 1 (0.7) 2 (1.3) 1 (0.7) 2 (1.3) Censored
Patients analysed
Genotyping-adjusted analysis N = 147 N = 148 N = 147 N = 145
Genotyping-unadjusted analysis N = 149 N = 150 N = 149 N = 150
mITT modified Intention To Treat, KM Kaplan-Meier, PP per protocol, ACPR Adequate Clinical and Parasitological Response, ETF Early Treatment Failure, LPF Late
Parasitological Failure, LCF Late Clinical Failure, PCR Polymerase Chain Reaction, SAE Serious Adverse Event.
* coded as Failure in genotyping -un-adjusted analysis.
** Plasmodium malariae infections.
# n=1 patient with SAE (= severe malaria due to re-infection with Pf malaria, ASAQ, day 30) is not listed here among SAE, but instead listed among the
re-infections (= efficacy endpoint).
## n=1 withdrawn following incorrect enrolment on day 0 (=asexual parasites density outside the eligibility range).
Table 3 Efficacy endpoint classification at day 28 and day 42, - PP / percent cured analysis
Treatment outcome Day 28 Day 42
PP population, N (%) ASAQ AL ASAQ AL % cured analysis
N = 142 N = 126 N = 142 N = 126
ACPR 99 (69.7) 108 (85.7) 75 (52.8) 71 (56.3) Success
ETF 0 (0) 1 (0.8) 0 (0) 1 (0.8) Failure
LCF or LPF
- P. falciparum recrudescence 1 (0.7) 2 (1.6) 3 (2.1) 5 (4.0) Failure
- P. falciparum re-infection 39 (27.5) 11 (8.7) 61 (43.0) 40 (31.7) Excluded*
- undetermined or missing PCR 2 (1.4) 2 (1.6) 2 (1.4) 5 (4.0) Excluded*
Non-P. falciparum malaria infection ** 0 (0) 2 (1.6) 0 (0) 4 (3.2) Excluded
No treatment outcome
- discontinued for SAE 1 (0.7) 0 (0) 1 (0.7) 0 (0) Excluded
Patients analysed
Genotyping-adjusted analysis N = 100 N = 111 N = 78 N = 77
Genotyping-unadjusted analysis N = 141 N = 124 N = 141 N = 122
mITT modified Intention To Treat, KM Kaplan-Meier, PP per protocol, ACPR Adequate Clinical and Parasitological Response, ETF Early Treatment Failure, LPF Late
Parasitological Failure, LCF Late Clinical Failure, PCR Polymerase Chain Reaction, SAE Serious Adverse Event. * coded as Failure in genotyping-unadjusted analysis.
** Plasmodium malariae infections.
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indicating a previous treatment with AQ (no violation).
On day 7, three patients had DEAQ values below the
LOQ (<2.5 ng/ml), suggestive of sub-optimal drug intake
or mal-absorption. All three patients had completed the
drug intake according to schedule and had day 42 efficacy
outcome ACPR. Five patients also had detectable AQ on
day 7, indicative of AQ intake before sample collection
(protocol violation) (range: 2.6-4.2 ng/ml). No LF blood
concentrations were detected in the AL arm at baseline.
On day 7, 33 patients had non-quantifiable LF concentra-
tions (< LOQ, 200 ng/ml). These were set as 100 ng/ml
(=LOQ/2) by convention for all blood concentration ana-
lyses, since the LOQ was considered very high.
The median day 7 DEAQ blood concentration of all pa-
tients in the ASAQ arm was 423 ng/ml (IQR 314, 602;
137/149 samples available and quantifiable, mITT). The
median day 7 LF concentration was 310 ng/ml (IQR 200,
447;139/150 samples available and quantifiable, mITT, AL
arm). The recrudescences in the ASAQ arm had day 7
DEAQ blood concentrations of 242, 401 and 688 ng/ml,
respectively. Recrudescences in the AL arm had day 7 LF
concentrations of 271, 447 and 515 ng/ml, respectively
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(n = 1 no sample available, n = 1 LF < LOQ). Comparison
of day 7 blood concentrations between patients with day
42 efficacy outcome ACPR versus recrudescence revealed
no significant differences for DEAQ (ASAQ arm, p =
0.641) or LF (AL arm, p = 0.775), respectively (Table 5).
Similarly, comparison of day 7 DEAQ drug concentrations
between ACPR versus re-infections or ACPR versus all P.
falciparum recurrences combined were not significantly
different (ASAQ arm: p = 0.209, p = 0.205, Table 5). Day 7
LF blood concentrations were significantly lower in pa-
tients with re-infection (p = 0.022) or in patients with any
type of P. falciparum recurrences (p = 0.015) when com-
pared to ACPRs (AL arm, Table 5). Similar results were
obtained when blood concentrations of patients with indi-
cation of recent AQ intake on day 0 or day 7 (protocol viola-
tion) or low DEAQ on day 7 (ASAQ arm), and patients
with day 7 LF values < LOQ (AL arm) were excluded from
all day 7 blood concentration comparison analyses.
Day 0 blood concentrations of other anti-malarials
Stored day 0 serum samples were retrospectively analysed
for detectable concentrations of other anti-malarials
(Table 6, mITT population). At baseline 17% (ASAQ arm)
and 10% (AL arm) of children had detectable concentra-
tions of chloroquine, 8.1% (ASAQ) and 4.0% (AL) had de-
tectable concentrations of sulphadoxine, 2% (ASAQ) and
4.7% (AL) had detectable quinine, and 1.3% (ASAQ) and
0.7% (AL) had detectable pyrimethamine, respectively.
Median drug concentrations are tabulated (Table 6).
Discussion
Since 2003, AS + AQ loose dose has been adopted as first-
line treatment for uncomplicated falciparum malaria in
Liberia. Published information on the efficacy of AS + AQ
or other forms of ACT in the country are currently limited
to only one observational study on the efficacy of
artemether-lumefantrine in Tubmanburg and Harper
region [14]. We report here on the in vivo efficacy of
two ACTs, ASAQ fixed-dose-combination (FDC) and
artemether-lumefantrine (AL) among 6–59 month old
children with uncomplicated falciparum malaria in
Nimba County, a highly Pf malaria endemic area in
Northern Liberia. The day 42 genotyping-adjusted cure
rate estimates of ASAQ and AL reached 97.3% and
94.2% respectively (mITT / KM). Both treatments were
well above the WHO-recommended 90% threshold for
treatments in use [10]. ASAQ FDC was shown to be
non-inferior to AL after 42 days of follow up in two par-
allel analytic approaches. Few treatment failures were
detected, but > 50% occurred after day 28 in both study
arms, arguing for 42 days follow up when monitoring
these two treatments. In the parallel tolerability trial
conducted among patients > 5 years, an age group likely
partially immune, day 28 genotyping-adjusted cure rates
of ASAQ and AL were also high (> 95%). Though the
limited malaria blood smear follow up in this second
trial should be considered. Both ASAQ and AL were
also well tolerated among children six to 59 month and
among the older age group (>5 years), as described else-
where in more detail [15].
Overall, efficacy results obtained in the present studies
were very good for both ACTs. This was also encour-
aging for the utility of ASAQ FDC in a geographical
setting where amodiaquine monotherapy and AS + AQ
(non fixed formulation, i.e. blister packs) were used for
several years. Notably however, anecdotal reports sug-
gested that the prescription of AS + AQ loose dose pro-
vided the opportunity to disregard the amodiaquine
compound, referring to patients’ and providers’ concern
on tolerability related to prescriptions of higher dose
Table 4 Genotype adjusted and non-adjusted day 28 and day 42 cure rates, and day 42 non-inferiority analyses
KM cure rate estimates Observed proportion cured
mITT population PP population
Day 28 ASAQ AL ASAQ AL
Genotyping-adjusted
% cured [95% CI] 99.3 [95.1–99.9] 97.9 [93.6–99.3] 99.0 [94.6–100] 97.3 [92.3–99.4]
Genotyping-unadjusted
% cured [95% CI] 71.2 [63.1– 77.9] 87.5% [80.9–91.9] 70.2 [61.9–77.6] 87.1 [79.9–92.4]
Day 42
Genotyping-adjusted
% cured [95% CI] 97.3 [91.6–99.1] 94.2 [88.1–97.2] 96.2 [89.2–99.2] 92.2 [83.8–97.1]
% difference # (UL 95% CI*) −3.1 (1.2) −3.9 (2.2)
Genotyping-unadjusted
% cured [95% CI] 52.7 [44.3–60.5] 59.5 [50.9–67.1] 53.2 [44.6–61.6] 58. 2 [48.9–67.1]
# Percent difference in day 42 genotyping-adjusted cure rate: AL arm day 42% cured- ASAQ arm day 42% cured. * According to the method of Blackwelder:
one-sided 95% upper limit (UL) CI of a two-sided 90% CI around the difference of efficacy of cure rates. The CI was assessed by Wald method.
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amodiaquine monotherapy in the past [21]. The present
findings were also in line with efficacy results recently
reported for ASAQ FDC and AL in Western-, Central-
and Southern African regions or India [6-9,22-24]. A re-
cent study also demonstrated good effectiveness of both
ASAQ FDC and AL among children ≤ 5 years following
unobserved treatment in Benin [25]. Taken together
these findings also open the possibility of using several
efficacious and well tolerable forms of ACT in the same
country, which may decrease drug pressure. As anti-
malarial drug efficacy may vary within regions and even
within countries, ideally therapeutic efficacy studies would
be performed regularly at representative sentinel sites if
this is feasible.
The proportion of parasitaemic patients on day 3 has
been reported as an interesting indicator for monitoring
artemisinin resistance [26]. Although this indicator re-
quires large sample sizes and accurate timing of sample
collection for precise estimates and is dependent on pre-
treatment parasite density, the low proportion of patients
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Figure 3 Pf Gametocyte carriage by malaria blood smear up to day 28, by treatment arm. Pf = Plasmodium falciparum. (A) Percentage of
patients with Pf gametocytes by blood smear among total patients by follow up day, by treatment arm, mITT population. (B) Percentage of patients
with Pf gametocytes by blood smear among patients who had no gametocytes on day 0, by follow up day, by treatment arm, mITT population.
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parasitaemic at day 3 for both ASAQ and AL in the
present study was nevertheless reassuring. The use of
more accurate estimations of parasite clearance rates with
recently developed tools should be preferred but demand
repeated parasitaemia measures [27]. Since sub-optimal
drug exposure is considered among the main reasons for
treatment failure, the day 7 blood concentration of the
slowly eliminated artemisinin-partner drugs was proposed
as a simplified and valid pharmacokinetic predictor of
treatment outcome [28]. Day 7 DEAQ or LF bloods con-
centrations in the present study were overall close to those
reported in two previous studies using whole blood sam-
ples on filter paper [19,29]. No evidence was found that
treatment failure in either study arm was linked with in-
adequate drug exposure when comparing day 7 DEAQ or
LF drug levels, respectively, among patients with ACPR
versus recrudescence. The comparison for recrudescences
was however limited by the few treatment failures.
Notably day 7 LF concentrations were significantly lower
among patients with re-infection than among patients
with ACPR, while this was not the case for day 7 DEAQ
concentrations. No direct correlation between day 7 drug
levels and re-infection has been established yet, and add-
itional measurements beyond day 7 would be needed for a
more robust analysis of a potential correlation. Fever clear-
ance was good in both treatment arms among the few
children who had presented with temperatures >37.5°C on
day 0. Gametocyte carriage was reduced significantly dur-
ing follow up. It seemed slightly slower in the ASAQ arm
than in the AL arm, as indicatedmainly by a higher percent-
age of gametocyte carriage on day 7.
The overall P. falciparum re-infection rate was high in
the present study, emphasizing the burden of malaria
among the non-immune < 5 year olds in Nimba County.
Re-infection rates were higher in the ASAQ arm than the
AL arm, and AL conferred a longer secondary prophylac-
tic effect than ASAQ with a significantly lower median
time to re-infection in the ASAQ arm. The current WHO
treatment protocol emphasizes the curative effect of the
anti-malarial treatment, i.e. a fast elimination of the para-
site [2]. A potentially increased risk of resistance develop-
ment has also been discussed for artemisinin partner
Table 5 Day 7 desethylamodiaquine- and lumefantrine blood concentrations by day 42 efficacy outcome and
treatment arm (mITT)
Study arm Compound Patients n/N # Day 42 efficacy endpoint Blood concentrations
[ng/ml] median (IQR)
Wilcoxon rank-sum
(Mann–Whitney) test ε
ASAQ DEAQ 73/77 ACPR 456 (167, 1727)
3/3 recrudescence1 402 (242, 688) p = 0.641
59/64 P. falciparum re-infection 410 (308, 525) p = 0.209
2/2 Recurrence with un-determined or missing PCR 525 (277, 772)
64/69 Recurrences combined2 407 (303, 525) p = 0.205
AL LF * 80/82 ACPR 356 (221, 547)
4/6 recrudescence1 359 (186, 481) p = 0.775
43/45 P. falciparum re-infection 295 (200, 363) p = 0.022
5/5 Recurrence with un-determined or missing PCR 254 (100, 262)
52/56 Recurrences combined2 276 (150, 373) p = 0.015
#n = Number of patients with blood concentration sample available and quantifiable among total N.
*n = 33 day 7 LF values were < LOQ. Values were set as LOQ/2 (=100 ng/ml).
1Recrudescence = LPF + LCF.
2Recurrences combined = Recrudescence, re-infection and recurrence with undetermined or missing PCR combined.
εComparison between day 7 drug concentrations of patients with day 42 efficacy outcome ACPR versus recrudescence, ACPR versus re-infection, ACPR versus Pf
recurrences combined.
AQ amodiaquine, LF lumefantrine, DEAQ desethylamodiaquine, mITT modified Intention To Treat population, ACPR Adequate Clinical and Parasitological Response,
Pf Plasmodium falciparum, PCR Polymerase Chain reaction.
Table 6 Day 0 serum concentration of other anti-malarial drugs, mITT population
Study arm ASAQ AL
N = 149* N = 150
Antimalarial drug detected Patients Serum concentration
[ng/ml] median (range)
Patients Serum concentration
[ng/ml] median (range)n (%) n (%)
Pyrimethamine 2 (1.3) 73 (10–135) 1 (0.7) 408 (408)
Sulphadoxine 12 (8.1) 49 (12–74323) 6 (4.0) 148 (22–123598)
Chloroquine 25 (16.9) 127 (10–559) 15 (10.0) 82 (11–572)
Quinine 3 (2.0) 32 (13–39) 7 (4.7) 413 (13–8511)
*samples available for 148 of 149 patients.
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compounds that confer longer post-treatment prophylaxis
[30,31], and the benefit of the prophylactic effect of an
anti-malarial may also need to be compared against other
essential elements, such as fast parasite elimination, good
tolerability, easy administration and good compliance.
In 2001 high resistance to chloroquine and sulphadoxine-
pyrymethamine (SP), the respective first- and second-line
treatments in the country at the time, were reported in the
Harper region, Liberia [32]. A second study showed that
amodiaquine (AQ) monotherapy still had relatively good
efficacy [32,33]. In 2003, AS-AQ combination therapy
(provided as co-blister-packed separate tablets) was adop-
ted as first-line treatment for uncomplicated falciparum
malaria in Liberia. Non-ACT, such as chloroquine and
amodiaquine are however still available and used by the
population in Liberia [21,34]. In the present study,
assessment of day 0 serum concentrations of various anti-
malarials indicated that a considerable proportion of chil-
dren had recent anti-malarial intake, mainly chloroquine
and sulphadoxine. These findings are not unexpected in a
highly endemic setting, and are unlikely to have impacted
much on the efficacy results. However, ongoing use of
non-ACT, including chloroquine which can evoke cross-
resistance to amodiaquine, re-emphasizes the need to en-
sure wide–spread and continuous access to the first-line
ACT while removing access and use of non-ACT. Follow-
ing the introduction of ASAQ FDC as first-line treatment
in 2010, the most recent Liberian Malaria Indicator survey
conducted in 2011 reported that for about seven out of 10
children who received an anti-malarial treatment, care-
takers indicated the use of an ACT (referring to “the new
malaria medicine”, i.e. ASAQ FDC) [21]. These findings
are encouraging and should be supported with ongoing
efficacy monitoring.
Conclusion
ASAQ and AL were both highly efficacious treatments for
uncomplicated falciparummalaria in Nimba County. These
findings support both drugs as treatment options. Since the
end of 2010, ASAQ FDC was adopted as national first-line
treatment in Liberia. As for all malaria endemic settings,
anti-malarial treatment monitoring should continue on a
regular basis, ideally including recently developed early in-
dicators of emerging artemisinin resistance.
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